Sun Pharmaceutical Industries Limited will host an analyst and institutional investor meeting on September 1, 2026. The event is scheduled as part of the Ashwamedh – Elara India Dialogue 2026 in Mumbai.

The company disclosed the schedule pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will feature both group and one-on-one sessions.

Meeting Details

Sun Pharma stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions. The schedule remains subject to change due to exigencies on either side.

Anoop Deshpande, Company Secretary and Compliance Officer, signed the intimation on August 25, 2026.

Sun Pharmaceutical Industries has secured a significant legal victory in the United States, with the Third Circuit Court of Appeals affirming summary judgment in its favor regarding antitrust litigation over generic Lipitor (Atorvastatin). The appellate court's decision denies class certification for plaintiffs and brings the long-standing dispute substantially to a close.

The litigation centered on a 2008 patent settlement agreement between Sun Pharma and Pfizer. Plaintiffs alleged that this settlement unlawfully delayed the entry of generic competition for Lipitor into the US market, arguing that absent the agreement, the generic version would have launched earlier.

Legal outcome

The United States Court of Appeals for the Third Circuit upheld the order from the United States District Court. The lower court had previously granted summary judgment in its entirety to Sun Pharmaceutical Industries Limited and certain of its subsidiaries.

Key aspects of the appellate decision are summarised below:

This outcome represents a favorable development for the company, removing a material legal overhang associated with the case. The matter is now considered substantially closed, subject only to any further remedies available to plaintiffs under applicable law.

Regulatory disclosure

The company disclosed the update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharma has consistently disclosed the status of this matter in its financial statements throughout the duration of the litigation.